Physician profile
Munawar Azam
NPI 1104859271
$8,444.03
in general payments reported to CMS, 2019-2025
31 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,195 · 2020: $1,125 · 2021: $1,180 · 2022: $1,076 · 2023: $1,141 · 2024: $1,047 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,828 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,828.32 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,429.27 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,167.75 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,091.97 | 2020-2025 | Ubrelvy, Qulipta, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $824.41 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $607.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $523.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $297.65 | 2019-2023 | |
| Pfizer INC. | $277.64 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $254.88 | 2019-2022 | |
| Abbott Laboratories | $221.07 | 2019-2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $198.82 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $172.49 | 2022-2025 | |
| Allergan, INC. | $167.51 | 2019-2020 | |
| Exact Sciences Corporation | $154.54 | 2025 | Cologuard Collection Kit |
| Neurelis, INC. | $140.83 | 2025 | Valtoco |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $111.64 | 2019-2021 | |
| Heartflow, INC. | $108.47 | 2025 | |
| Currax Pharmaceuticals LLC | $92.20 | 2020-2023 | Contrave |
| Resmed Corp | $86.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.54 | 2022-2023 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $72.20 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $70.09 | 2025 | Vowst |
| Amarin Pharma, INC. | $62.36 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $57.76 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $50.52 | 2019 | |
| Sunovion Pharmaceuticals INC. | $43.40 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.67 | 2022 | |
| Dexcom, INC. | $17.28 | 2024 | Dexcom G6 Transmitter |
| Ferring Pharmaceuticals INC. | $15.47 | 2024 | Rebyota |
| Biohaven Pharmaceuticals, INC. | $14.34 | 2021 | |
| Bausch Health US, LLC | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munawar Azam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.